GE Healthcare announced the company has signed a research agreement with Brigham and Women's Hospital, a 777-bed teaching affiliate of Harvard Medical School, to establish a landmark alliance in medical research in area of Positron Emission Tomography (PET). The agreement is expected to leverage GE Healthcare's Molecular Imaging (MI) research efforts, quickly transitioning those discoveries into the clinical environment.
"Collaborations of this caliber are direct investments in the future of healthcare," said Terri Bresenham, vice president of the GE Healthcare Molecular Imaging business. "Brigham and Women's world-class patient care, in conjunction with their stellar research and clinical-trial track record, make them an optimal partner in discovering new MI technologies to diagnose and treat disease."
Brigham and Women's Hospital has consistently been a leader in the adoption of new medical imaging technologies and establishing their value in the clinic. Clinicians and scientists from both BWH and GE Healthcare plan to use the tools of molecular imaging and radiopharmaceutical development to further the cause of developing personalized approaches to the diagnosis and management of patients with oncologic, neurologic and cardiovascular diseases.
The collaboration of GE Health Care's resources in chemistry, biology, drug development, engineering and imaging technology with BWH strengths in clinical research create a partnership with unlimited potential to improve the care of patients," said Steven Seltzer, MD, chairman, Department of Radiology at BWH.
GE Healthcare's Molecular Imaging is the future of medicine in the 21st Century. With 2,500 scientists at GE's Global Research Centers, and important clinical partners around the world, GE is the leader in this field, with the depth and breadth of talent to answer healthcare's unmet need.
"The more we understand about disease from a clinical standpoint, the better equipped we are to build technologies to improve patient care," said Jean-Luc Vanderheyden, GE Healthcare's Global Molecular Imaging Leader. "This collaboration has the ability accelerate the process of developing more effective methods of diagnosing, treating and monitoring disease."
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company. Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.